Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706462 | 0.85 | KDM4E (0.34) | RIPK1 | |
| SCHEMBL13349600 | 0.66 | RIPK1 (0.35) | RIPK1 | |
| SCHEMBL12091514 | 0.66 | LMNA (0.31) | — | |
| SCHEMBL3297238 | 0.62 | PYGL (0.34) | — | |
| SCHEMBL12200519 | 0.61 | SMO (0.34) | — | |
| SCHEMBL17077854 | 0.61 | — | — | |
| SCHEMBL16862140 | 0.60 | PLA2G7 (0.35) | RIPK1 | |
| SCHEMBL16861838 | 0.60 | CYP2C19 (0.42) | RIPK1 | |
| SCHEMBL2737003 | 0.59 | RIPK1 (0.59) | RIPK1 | |
| SCHEMBL9491351 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592202-B2 | Method to stabilize a dietary supplement to facilitate joint health in humans | WYETH LLC (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2429500-B1 | METHOD TO STABILIZE A DIETARY SUPPLEMENT COMPRISING GLUCOSAMINE | WYETH LLC (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2429500-A1 | METHOD TO STABILIZE A DIETARY SUPPLEMENT COMPRISING GLUCOSAMINE | Wyeth LLC (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010141191-A1 | METHOD TO STABILIZE A DIETARY SUPPLEMENT COMPRISING GLUCOSAMINE | WYETH LLC (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100291240-A1 | Method to Stabilize a Dietary Supplement to Facilitate Joint Health in Humans | WYETH LLC (US) | 2010-11-18 | — | — | US | disclosed |
| EP-1704862-A1 | 2,5-bis(tetrahydroxybutyl)pyrazines for the treatment of osteoarthritis and rheumatoid arthritis | Rottapharm S.p.A. (IT) | 2006-09-27 | — | — | EP | disclosed |
| EP-1704862-A1 | 2,5-bis(tetrahydroxybutyl)pyrazines for the treatment of osteoarthritis and rheumatoid arthritis | Rottapharm S.p.A. (IT) | 2006-09-27 | — | — | EP | disclosed |
| US-20020051828-A1 | Mixtures which can be isolated from eugenia jambolana lamarck seeds, their preparation and the use of these mixtures and some of their constituents as medicaments | RHONE-POULENC RORER S.A. AND INSTITUT MALGACHE DE RECHERCHES APPLIQUEES | 2002-05-02 | — | — | US | disclosed |
| US-6300375-B1 | ADMINISTERING SODIUM OXAMATE FOR PROPHYLAXIS OR THERAPY OF DIABETES OR COMPLICATIONS DUE TO DIABETES | RHONE-POULENC RORER SA (FR) | 2001-10-09 | — | — | US | disclosed |
| EP-0879058-B1 | MIXTURES DERIVED FROM GRAINS OF EUGENIA JAMBOLANA LAMARCK, PREPARATION AND USE OF SAID MIXTURES AND SOME OF THEIR CONSTITUENTS AS MEDICAMENTS | INST MALGACHE DE RECH S APPLIQ (MG) | 2001-06-06 | — | — | EP | disclosed |
| US-6194412-B1 | ANTIDIABETIC AGENTS | RHONE-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | disclosed |
| US-5972342-A | ANTIDIABETIC AGENTS | RHONE-POULENC RORER S.A. (FR) | 1999-10-26 | — | — | US | disclosed |
| EP-0879058-A1 | MIXTURES DERIVED FROM GRAINS OF EUGENIA JAMBOLANA LAMARCK, PREPARATION AND USE OF SAID MIXTURES AND SOME OF THEIR CONSTITUENTS AS MEDICAMENTS | Institut Malgache de Recherches Appliquées (MG) | 1998-11-25 | — | — | EP | disclosed |
| WO-1997028813-A1 | MIXTURES DERIVED FROM GRAINS OF EUGENIA JAMBOLANA LAMARCK, PREPARATION AND USE OF SAID MIXTURES AND SOME OF THEIR CONSTITUENTS AS MEDICAMENTS | INSTITUT MALGACHE DE RECHERCHES APPLIQUEES (MG) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020051828-A1 | Mixtures which can be isolated from eugenia jambolana lamarck seeds, their preparation and the use of these mixtures and some of their constituents as medicaments | CMPK1, LNPK, SYMPK | RIPK1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.